Several factors influence tirzepatide's pharmacokinetics: Elimination pathway : Tirzepatide is primarily eliminated through proteolytic breakdown in the body, not through renal excretion Dose and duration of treatment : Higher doses and longer treatment periods result in greater drug accumulation Body weight : Body weight is a known covariate that can modestly affect drug exposure Steady-state concentrations : With weekly dosing, tirzepatide reaches steady-state levels after approximately 4 weeks of consistent administration According to FDA prescribing information, no dose adjustment is required for patients with renal impairment (including end-stage renal disease) or hepatic impairment, as these conditions do not significantly affect tirzepatide clearance
Although Roche and Eli Lilly have experienced drug failures in this regard, Biogens antibody to A, aducanumab (BIIB-037), has moved into Phase III clinical trials with promising results at low doses [27]
Biochem Res Int 2012:213403
329 NelsonMJBahlJSBuckleyJDThomsonRLDavisonK
This research was funded in part by Centro de Investigacin Biomdica en Red de Enfermedades Hepticas y Digestivas (CIBEREHD), Instituto de Salud Carlos III, Subdireccin General de Investigacin Sanitaria, Ministerio de Economa y Competitividad (Madrid): EHD16PI02 (RF)
[DOI] [PMC free article] [PubMed] [Google Scholar] 83.Novak V., Milberg W., Hao Y., Munshi M., Novak P., Galica A., Manor B., Roberson P., Craft S., Abduljalil A
